Angiotensin induces inflammatory activation of human vascular smooth muscle cells

R Kranzhöfer, J Schmidt, CAH Pfeiffer… - … , and vascular biology, 1999 - Am Heart Assoc
R Kranzhöfer, J Schmidt, CAH Pfeiffer, S Hagl, P Libby, W Kübler
Arteriosclerosis, thrombosis, and vascular biology, 1999Am Heart Assoc
Multiple data suggest that the renin-angiotensin system contributes to the pathogenesis of
atherosclerosis. The atherogenic effect of the renin-angiotensin system can only in part be
explained by the influence of its effector angiotensin II on blood pressure, smooth muscle
cell (SMC) growth, or antifibrinolytic activity. Because chronic inflammation of the vessel wall
is a hallmark of atherosclerosis, we hypothesized that angiotensin II may elicit inflammatory
signals in vascular SMCs. Human vascular SMCs were stimulated with angiotensin …
Abstract
—Multiple data suggest that the renin-angiotensin system contributes to the pathogenesis of atherosclerosis. The atherogenic effect of the renin-angiotensin system can only in part be explained by the influence of its effector angiotensin II on blood pressure, smooth muscle cell (SMC) growth, or antifibrinolytic activity. Because chronic inflammation of the vessel wall is a hallmark of atherosclerosis, we hypothesized that angiotensin II may elicit inflammatory signals in vascular SMCs. Human vascular SMCs were stimulated with angiotensin. Inflammatory activation was assessed by determination of interleukin-6 (IL-6) release into the culture medium, detection of IL-6 mRNA by RT-PCR, and demonstration of activation of nuclear factor-κB in electrophoretic mobility shift assays. Angiotensin II concentration-dependently (1 nmol/L to 1 μmol/L) stimulated IL-6 production by SMCs via activation of the angiotensin II type 1 receptor (demonstrated by the inhibitory action of the receptor antagonist losartan). Angiotensin I increased IL-6 production by SMCs, too. This effect was inhibited by captopril and ramiprilat, suggesting conversion of angiotensin I to angiotensin II by angiotensin-converting enzyme in SMCs. Steady-state mRNA for IL-6 was augmented after stimulation with angiotensin II, suggesting regulation of angiotensin-induced IL-6 release at the pretranslational level. Moreover, the proinflammatory transcription factor nuclear factor-κB, which is necessary for transcription of most cytokine genes, was also activated by angiotensin II. Pyrrolidine dithiocarbamate suppressed angiotensin II–induced IL-6 release, a finding compatible with involvement of reactive oxygen species as second messengers in cytokine production mediated by angiotensin. The data demonstrate the ability of angiotensin to elicit an inflammatory response in human vascular SMCs by stimulation of cytokine production and activation of nuclear factor-κB. Inflammatory activation of the vessel wall by a dysregulated renin-angiotensin system may contribute to the pathogenesis of atherosclerosis.
Am Heart Assoc